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Letter
Radiation recall myelitis following paclitaxel chemotherapy:  
The first reported case
Shearwood McClelland III, MD1, Paul H Cooper, CMD1, Anupama K Acheson, MD2, Jeremy N Ciporen, MD3, 
Jerry J Jaboin, MD, PhD1 and Timur Mitin, MD, PhD1
1Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA
2Providence Cancer Center, Portland, OR, USA
3Department of Neurological Surgery, Oregon Health and Science University, Portland, OR, USA
Correspondence to: Shearwood McClelland III, MD, Department of Radiation Medicine, Oregon Health and Science 
University, 3181 SW Sam Jackson Park Rd, L337, Portland, OR 97239-3098, USA; Email: drwood@post.harvard.edu;  
Phone: +1 (503) 681-4200; Fax: +1 (503) 681-4210
(Received: June 7, 2018; Accepted: June 26, 2018)
ABSTRACT
Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly 
utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 
2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report 
a patient who developed myelitis following spinal SBRT to a region with existing hardware. 
Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis 
and underwent tumor debulking with posteriorly instrumented T3-T5 fusion. Postoperatively she 
proceeded with SBRT to the T3-T5 vertebral bodies, receiving 30 Gy in 6 Gy/fraction. Seven months 
later, she required paclitaxel chemotherapy (80 mg/m2 per cycle) for new liver metastases. 
Results: Eight months following spine SBRT, four weeks after having started chemotherapy she 
developed intractable back pain and right lower extremity numbness which improved upon receiving 
steroids for weekly chemotherapy; the numbness subsequently spread to her left leg. Thoracic spine 
MRI revealed a 1.7 cm ovoid focus of T4-T5 spinal cord enhancement with extensive surrounding cord 
edema extending superiorly to C6-C7, consistent with radiation myelitis. Hyperbaric oxygen moderately 
improved her symptoms; fortunately, she never developed motor symptomatology or bowel/bladder 
dysfunction. Thorough re-evaluation of the original thoracic spine SBRT plan revealed no deviations 
from the standard of care, nor did re-planning with alternate treatment planning software demonstrate 
any significant difference in maximum cord dosage than the original plan. 
Conclusions: The timing of symptomatology related to chemotherapy administration is consistent 
with radiation recall myelitis, which has yet to be reported following SBRT. Given the potentially 
disastrous consequences of myelitis, patients with metastatic disease previously treated with spine 
SBRT may be susceptible to developing myelitis if treated with paclitaxel chemotherapy.
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IntroductIon
Stereotactic body radiotherapy (SBRT) of the spine has 
become an increasingly utilized modality in the United 
States, most commonly for metastatic disease (1). The 
safety and efficacy of spine SBRT has been validated from 
studies with short-term and multi-year follow-up (2-3). The 
phenomenon of radiation recall myelitis has been reported 
only once in the literature, in a metastatic melanoma patient 
receiving dabrafenib after having previously received ste-
reotactic radiotherapy for a lung metastasis (4). We present 
the first report of radiation recall myelitis following spinal 
SBRT in a patient after receiving chemotherapy.
case report
A 55-year-old woman with Stage IV breast cancer 
developed a T4 vertebral body mass despite optimal treat-
ment, which extended into the neural foramina at T3-T4 and 
T4-T5 in close proximity to the exiting T3 and T4 nerve 
roots as well as epidural space involvement. She elected to 
undergo T4 tumor debulking with posterior decompressive 
laminectomies at T3 and T4 with posterior instrumented 
T3-T5 fusion (four threaded TI Matrix screws with two 
TI curved rods, Depuy Synthes, Raynham, MA); histopa-
thology revealed this mass to be metastatic breast cancer. 
After postoperative discussion in our RADIANS (RADIa-
tion oncology And NeuroSurgery) multidisciplinary clinic, 
the patient elected to proceed with SBRT to the T3-T5 
spine, receiving 30 Gy in 6 Gy per fraction; this plan was 
performed using the Pinnacle treatment planning system 
(Philips Radiation Oncology; Fitchburg, WI) (Figure 1) (5).
Unfortunately, seven months after SBRT she 
required chemotherapy for new liver metastases. Four 
weeks after starting intravenous paclitaxel (80 mg/m2 
weekly for a five-week course) for chemotherapy ( 
eight months following her spine SBRT), she devel-
oped intractable back pain with right lower extrem-
ity numbness which improved upon receiving steroids 
for weekly chemotherapy only to return within each 
week; this numbness subsequently spread to her left 
leg. The persistence of these symptoms prompted a 
thoracic spine MRI eight days after initial symptom 
onset which revealed a 1.7 cm ovoid focus of spinal 
cord enhancement at T4-T5 with extensive surround-
ing cord edema extending superiorly to C6-C7, con-
sistent with radiation myelitis (Figure 2). She was 
treated with a six-week course of steroids which 
unfortunately failed to alleviate her symptoms; how-
Figure 1. Axial isodose plan of original T3-T5 vertebral 
body SBRT plan
Figure 2. Sagittal T1-weighted thoracic spine MRI 
demonstrating spinal cord myelitis at the T4-T5 level 
consistent with radiation recall myelitis.
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ever, she never developed motor symptomatology 
or any bowel/bladder dysfunction secondary to the 
myelitis; by this time her fifth and final cycle of pacli-
taxel chemotherapy had concluded. Subsequently, she 
elected to undergo hyperbaric oxygen treatment (nine 
weeks after initial symptom onset), during which her 
symptoms moderately improved. 
Due to the rarity of radiation-induced myelitis, a 
thorough re-evaluation of the original thoracic spine 
SBRT plan was performed, revealing no deviations 
from the standard of care (5). Subsequently, a re-plan-
ning exercise was performed using the Monaco treat-
ment planning software (Elekta; Stockholm, Sweden), 
which revealed a maximum spinal cord dosage within 
2% of the original Pinnacle plan, both well in accord-
ance to the spinal cord dose constraints established by 
Folkert and Timmerman (6). 
dIscussIon
The proximity of metastatic bony spine disease to 
the spinal cord itself has been a theoretical cause for 
hesitation when large radiation doses have been pro-
posed for treatment. However, several studies have 
established the safety and efficacy of spinal SBRT for 
metastatic disease, as well as appropriate parameters to 
minimize the morbidity of radiation therapy (2-3, 6). 
Given that our center has safely treated patients with 
indwelling hardware with spinal SBRT in the past with-
out morbidity and that previous series involving instru-
mented patients demonstrated no increased spine SBRT 
short or long-morbidity, it is highly unlikely that the spi-
nal instrumentation precipitated the myelopathy in our 
patient (3, 5). Our re-planning session using a different 
software system did not indicate a significant difference 
between the Monaco and Pinnacle treatment planning 
systems, both of which yielded a maximum spinal cord 
dose well within the established standard of care (6).
Having ruled out these potential causes of this 
patient’s myelopathy, the most logical explanation 
is a radiation recall phenomenon, which commonly 
manifests as myositis, but has only been reported mani-
festing as myelitis once before (4). In that case, the 
radiation recall occurred at a similar time frame fol-
lowing completion of radiation after the start of chemo-
therapy – seven months in that case and eight months 
in our patient. The recall in the previously reported case 
occurred after the patient received dabrafenib, a BRAF 
inhibitor demonstrated to improve overall survival in 
metastatic melanoma (7). In our case, radiation recall 
myelitis manifested after our patient was exposed to 
paclitaxel. Fortunately, hyperbaric oxygen was able to 
provide her with some symptom relief for her radiation 
myelitis, as has been previously reported (8).
First described in 1959, radiation recall manifests as 
an acute inflammatory reaction confined to previously 
irradiated areas triggered by administration of precipi-
tating systemic agents after radiation treatment (9-10). 
Approximately 2/3 of radiation recall cases manifest 
as skin toxicity, with the remaining 1/3 manifesting as 
toxicity in previously irradiated internal organs (10). 
Paclitaxel has demonstrated radiosensitization properties 
in the central nervous system related to its induction of 
G2-M cell cycle arrest, and been previously associated 
with radiation recall (10-11). This is the first report of 
radiation recall myelitis secondary to paclitaxel admin-
istration. As weekly paclitaxel is a standard regimen 
for metastatic breast cancer, it is imperative for medical 
oncologists to be aware of previously irradiated regions 
and proactively be on the lookout for radiation recall. 
Such action requires frequent communication with radia-
tion oncologists to ensure timely identification and treat-
ment of radiation recall symptoms.
conclusIon
This report of radiation-induced myelitis following 
spine SBRT manifesting within weeks after paclitaxel 
chemotherapy administration for metastatic breast 
cancer is consistent with radiation recall myelitis, 
which has yet to be reported following SBRT. Given 
the potentially disastrous consequences of myelitis, 
patients with metastatic disease previously treated with 
spine SBRT may be susceptible to developing myelitis 
if treated with paclitaxel chemotherapy. Further study 
is needed to better understand the pathophysiology of 
this phenomenon.
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